|[May 03, 2012]
Research and Markets: India Pharmaceutical Industry Research and Forecast to 2016
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/4lkwn7/india_pharmaceutic)
has announced the addition of the "India
Pharmaceutical Industry Research and Forecast to 2016" report
to their offering.
The report titled India Pharmaceutical Industry Research and Forecast to
2016 offer detailed analysis on the country's bulk and formulations
market which is sub-segmented into OTC, prescription drugs and generic
drugs. It analyses major bio-pharmaceutical market segments, top
therapeutic categories and traditional medicine market (herbal drugs,
ayurvedic and homeopathy). Report also include SWOT analysis, major
driving forces, industry growth barriers, Opportunities, Regulatory
structure, Macro economy factors and Political environment of the
country. Report also profile major players (domestic and international)
and forecast industry and its segments' growth.
Generic drugs have a dominant position in the rapidly expanding Indian
pharmaceutical industry. Inda is among one of the largest bulk drugs
exporters but represent only one fourth of the total pharmaceutical
market while formulation drugs account for the three fourth shares.
Domestic market has showcased resilience during the economic crisis and
has recorded a steady growth. Rising aging population indicates
compelling opportunity for drug manufacturers to focus on bone health,
dietary supplements and dementia and other age related diseases. Direct
marketing is in its development stage in the country while multi level
marketing companies are trying hard to understand spending behavior of
middle class population in India.
Biopharmaceutical sector is expected to witness double digit growth led
by major developments in therapeutic segment. Vaccines market (human and
animal) is enjoying a continuous growth, dominated by human vaccine
segment which accounted for more than three fourth of the market.
In-licensing deals are expected to increase in domestic market to take
the benefit of the lower R&D cost and manufacturing units of the
domestic generic companies. The generic segment is expected to grow at a
faster rate from 2012 onwards although industry may witness price
erosion leading to reduced generic player's profit margin.
Key Topics Covered:
1. Indian Healthcare Industry
2. India Pharmaceutical Market Segments
3. Classification on the basis of API manufacturing segments
4. Growth Drivers
6. SWOT Analysis
7. Growth Barriers
8. Recent Pharmaceutical Industry M&A's
9. Regulatory Structure
10. Country Analysis
11. Industry Competition and Domestic Players Profiling
- DR. Reddy's
- Sun Pharma
- Aurobindo pharmaceuticals
- GSK India
- Abbott India
- Novartis India
For more information visit http://www.researchandmarkets.com/research/4lkwn7/india_pharmaceutic.
[ Back To TMCnet.com's Homepage ]